Summary: Synthetic direct inhibitors of factor Xa are capable of prolonging the global anticoagulant assay times in a concentrationdependent fashion. The relative degree of thrombin generation inhibition at an equivalent prolongation is not similar to the results observed with heparins and oral anticoagulant drugs. In addition, the direct factor Xa inhibitors prolong the Russell's viper venom test (RVVT) and Heptest clotting times. Ecarin clotting time (ECT) and thrombin time (TT) remain unaffected. The kinetics of factor Xa inhibition are markedly different than those observed with pentasaccharide and heparins. Therefore, the methods developed for heparins and pentasaccharides may not be applicable for the monitoring of factor Xa inhibitors. To test the feasibility of using the prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), Heptest, thrombin time, RVVT, ECT, and a modified anti-Xa amidolytic assay, to monitor a synthetic factor Xa inhibitor, normal human pool plasma samples were spiked with a synthetic factor Xa inhibitor in the concentration range of 0 to 1 tg/mL and 0 to 25 ,g/mL. Different laboratory tests were performed and INR and other ratios were calculated. The anticoagulant effects on whole blood were measured using the activated clotting time (ACT). Further studies on the effect of factor Xa inhibitor on platelet aggregation; factor II, VII, and X functional levels; and fibrinopeptide A (FPA) generation were carried out at equivalent INR levels in comparison to oral anticoagulant and antithrombin agents. FPA generation at equivalent anticoagulant level in comparison to heparin (twice the baseline) was also carried out. Factor Xa inhibitor produced a concentration-dependent prolongation of the ACT (1) (2) (3) (4) . In this study, we modified the incubation time in the anti-Xa assay and determined that the modified anti-Xa assay has better sensitivity to factor Xa inhibitor. Earlier reports from our laboratory described the in vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low-molecular-weight derivative (PK 10169) (5) . The role of DX-9065a, a synthetic inhibitor of factor Xa, reduced proliferation of vascular smooth muscle cells in vivo in rats, has been reported (6). Yamazaki and associates reported the effect of DX-9065a, an orally active and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats (7) . The inter-assay variability in anti-Xa monitoring during treatment with lowmolecular-weight heparin or danaparoid was reported earlier (8) . Rai and associates provided perspectives on factor Xa inhibition (9) . Recent reports presented the heparin anti-Xa therapeutic range (10, 11 ,ug/mL, respectively. These clotting times were 2.5-, 3.0-, and 4.5-fold times baseline values, respectively. Fig. 2 shows a comparison of the ACT response of unfractionated heparin at 2.5 U/mL, pentasaccharide at 10 U/mL, enoxaparin at 25 U/mL, and JTV-803 at 25 ,utg/mL. Each agent prolonged the ACT to varying degrees based on their potency.
The 4 PT reagents used in this study exhibited ISI values ranging from 0.89 to 2.41. A concentration-dependent anticoagulant effect of JTV-803 using four different PT reagents was observed (Fig. 3) . The response to PT reagents in decreasing order of activity is recombiplastin > innovin > thromboplastin C = simplastin.
As depicted in Fig. 4 , there are differences in the INR values as measured by different reagents in plasma samples supplemented with factor Xa inhibitor over a concentration range 0 to 1 ,ug/mL. The INR response observed with different PT reagents in decreasing order of activity is thromboplastin-C > simplastin > innovin = recombiplastin.
Fig. 5 shows the data for the INR/PT ratio. Each reagent showed a different INR/PT ratio in the concentration range of 0 to 1 ,ug/mL.
The effect of JTV-803 supplemented in normal human plasma in the concentration range of 0 to 25 ,ug/mL was studied using diluted (1:2 in saline) PT ,ug/mL. Thus, the sensitivity of the PT response to factor Xa inhibitor could be increased by performing diluted PT assay. A concentration-dependent effect of JTV-803 on the aPTT assay using three different aPTT reagents was observed (Fig. 7) . Platelin and Stago reagents show a similar response, but Actin®., activated cephaloplastin reagent, shows a lower response than other aPTT reagents.
The effect of JTV-803 supplemented in normal human plasma in the concentration range of 0 to 25 Ag/mL was studied using diluted (1:2 in saline) aPTT reagents as shown in Fig. 8 . Diluted reagents showed a marked sensitivity to factor Xa inhibitor compared to undiluted reagents in the aPTT assays.
At the lower concentrations (0 to 1 Ag/mL), the Heptest clotting time was not prolonged and, therefore, is of no value in the monitoring of synthetic factor Xa inhibitors (Fig. 9 ). There was a twofold increase in the Heptest values at the concentration of 8 Atg/mL. On the contrary, other agents that inhibit factor Xa such as unfractionated heparin (UFH), enoxaparin, and pentasaccharide show a significant prolongation of Heptest clotting time and hence this test is useful in monitoring these agents. Reagent-dependent differences in INR were observed such that INR values at a concentration of 1 pg/mL were 3.9, 1.7, 1.8, and 2.8 with thromboplastin-C, innovin, recombiplastin, and simplastin, respectively.
As shown in Fig. 10 , the dRVVT is a sensitive assay for monitoring JTV-803. A concentrationdependent anticoagulant effect of JTV-803 supplemented in normal human plasma was observed. As seen in Fig. 11 , the thrombin time and ECT are not affected by JTV-803 in the concentration range of 0 to 25 ,ug/mL.
The anti-Xa effect of JTV-803 was also studied using an amidolytic assay. Factor Xa inhibitor supplemented in normal human plasma in the concentration of 0 to 25 ,g/mL was studied using modified anti-Xa method. The reaction time was decreased to 75 seconds instead of 300 seconds as in the conventional method. The modified assay showed a marked sensitivity when compared with conventional anti-Xa method. With the modified anti-Xa method, JTV-803 concentration as low as 2.5 ,uLg/mL can be measured. A comparison of the anti-Xa activity of factor Xa inhibitors as studied using the original and modified amidolytic assays is shown in Fig. 12 .
As seen in Fig. 13 gen activator. Urokinase and chymotrypsin were not affected (Fig. 14) .
The effect of JTV-803 on TAFI and TFPI was studied in the concentration range of 0 to 10 Ag/mL. As shown in Fig. 15 , a dose-dependent decrease in the TAFI levels was observed. However, it did not alter the TFPI levels (Fig.  16) . Fig. 17 shows the inhibition of FPA generation by JTV-803. Approximately 50% FPA generation inhibition was seen with PT reagent when factor Xa inhibitor was supplemented in normal human plasma. Similarly, a 60% and 40% FPA generation inhibition was observed with aPTT and PT/aPTT reagents, respectively. DISCUSSION These results suggest that synthetic factor Xa inhibitors can prolong the PT assay in a concentration-dependent fashion. The PT effects with thromboplastin-C, innovin, and simplastin are similar; however, recombiplastin gives slightly higher PT monitoring high concentrations of factor Xa inhibitors during percutaneous interventions. Amidolytic anti-Xa assay is a sensitive measure to monitor the levels of some factor Xa inhibitors such as pentasaccharide and DX-9065a (11) . However, this test is less sensitive at lower concentrations of the factor Xa inhibitor agent used in this study. To enhance the sensitivity of this assay, the incubation time of the assay was shortened.
Thrombin-specific tests such as the thrombin time and ecarin clotting time were not affected by JTV-803 at concentrations up to 25 ,ug/mL.
The aPTT assay shows a concentration-dependent effect. Three different aPTT reagents were used to perform the aPTT assay (Platelin, Actin®, and Stago). When the PT and aPTT reagents were diluted with saline (1:2), the sensitivity of these assays was markedly enhanced. The diluted PT and aPTT assays may also be used to monitor the anticoagulant effect of factor Xa inhibitor. To compare the sensitivities of various assays for measuring factor Xa inhibitor; we calculated the concentration that resulted in a doubling of the clotting time. Dilute PT and dilute aPTT assays showed increased sensitivity relative to the undiluted assays. The PT and dRVVT tests were also found sensitive. The Heptest assay was found to be less sensitive when compared to aPTT assay. Prolongation of the dRVVT is a sensitive measure of factor Xa inhibitor levels. The amidolytic anti-Xa method can be modified to detect the factor Xa inhibitors. Plasma levels of factors II, VII, and X were decreased in plasma supplemented with FXaI.
In the platelet aggregation assays, JTV-803 markedly inhibited the platelet aggregation response in a concentration-dependent fashion. The strongest inhibitory effect on platelets was observed when epinephrine was used as an agonist.
As can be seen in The aPTT test is relatively more reliable in measuring the anticoagulant actions of JTV-803. However, reagent-based variations have been observed with the aPTT as well. The Stago reagent is more sensitive to the anticoagulant actions of factor Xa inhibitor. A more sensitive and stable aPTT reagent may be useful for monitoring the anticoagulant effects of factor Xa inhibitors.
The diluted formulations of the PT and aPTT provide a more sensitive test for monitoring the anticoagulant activity of the factor Xa inhibitor. Such formulations may be able to provide increased sensitivity required to monitor lower levels of factor Xa inhibitors. It must be emphasized that these studies have been carried out using only one lot of JTV-803. Agent-specific variations may be observed. The relative sensitivity of the tests varies and specific formulations may require additional studies.
Modification of the anti-Xa method enhanced the sensitivity of this assay in measuring JTV-803 and may be used to monitor this agent effectively. Further studies are warranted to evaluate these results in clinical trials.
